WCLC 2021 | WCLC 2021: from patient-driven research to exciting future therapies

Jill Feldman, BS, MA, Lung Cancer Patient and Advocate, EGFR Resisters, shares some highlights from the WCLC 2021 meeting, specifically the reports on patient-driven research and the importance of real-world data complementing existing clinical research. Ms Feldman outlines recent research that revealed reduced screenings and increased deaths due to the COVID-19 pandemic, and the plenary sessions which reported much-needed investigations into risk factors such as air pollution in the development of lung cancer. Multiple plenary sessions had also reported on global disparities in the field of lung cancer and on rising drug prices in the US between 2015 and 2020. Ms Feldman is hopeful of future therapies for patients with lung cancer, such as the development of antibody conjugates and targeted treatments for patients carrying the exon 20 EGFR mutation. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.